Torti Frank
- SEC CIK
- 0001647805
In the past year, 1 open-market sale filing worth $82.0M and no purchases.
Current role at each company
- ROIV Roivant Sciences Ltd.President and Vant Chairas of Jul 2, 2026
- IMVT Immunovant, Inc.Directoras of Apr 9, 2026
- ABUS Arbutus Biopharma CorpDirectoras of May 24, 2024
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- $82.0M
- 1 filing
- Net
- −$82.0M
- Bought minus sold
- Companies
- 1
- With open-market trades
Trades
Every Form 4 that lists Torti Frank as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
ROIV Roivant Sciences Ltd.
President and Vant Chair1 trade
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Feb 23, 2026 (view filing) | Feb 19-23 | 4 days | Torti FrankPresident and Vant Chair | SSale | −3.00M | $27.35 | −$82.0M | −17.9%13.7M after | 3 lots10b5-1 |
IMVT Immunovant, Inc.
Director1 trade
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 29, 2022 (view filing) | Sep 29 | Same day | Torti FrankDirector | PPurchase | +20.0K | $5.81 | +$116.2K | +5.4%393.4K after |